Pfizer’s $110 billion bid for AstraZeneca was one of the biggest business stories of 2014 – so could a new bid be one of the biggest stories in 2015?» Read More
Stocks edged higher on Monday as investors tracked corporate results as the earnings season starts to wind down.
Some of Monday's midday movers:
Businesses say their growth plans could be seriously threatened by a lack of water availability. And the the threat could become real within a year.
Researchers, companies and Wall Street are gathering to gain a sense of bringing potentially multibillion dollar drugs to market.
LONDON, Nov 6- AstraZeneca, which saw off a $118 billion bid from Pfizer in May, said quarterly results showed its standalone strength, while recent U.S. tax changes removed much of the case for a new takeover attempt. Chief Executive Pascal Soriot, who has fought hard to prove AstraZeneca does not need the kind of mega-merger offered by Pfizer, said he would use the...
LONDON, Nov 6- AstraZeneca raised its 2014 sales forecast for the second quarter in a row on Thursday, as the delayed arrival of generic copies of its Nexium drug in the United States kept cash flowing from the heartburn and ulcer pill. Britain's second biggest drugmaker, which saw off a $118 billion takeover bid from Pfizer in May, now expects revenue to grow in low...
LONDON, Nov 6- AstraZeneca raised its 2014 sales forecast for the second quarter in a row on Thursday, as the delayed arrival of Nexium generics in the United States kept cash flowing from the heartburn and ulcer pill. Britain's second biggest drugmaker, which saw off a $118 billion takeover approach from Pfizer in May, now expects revenue to grow slightly this...
Global pain will mean U.S. gain at least in terms of stock market investing, according to a strongly bullish analysis from Mario Gabelli's team.
Stocks fell Tuesday as the price of oil slid to a three-year low.
Boehringer and Lilly will continue to jointly develop and market these drugs in 17 countries, including the United States, they said in a statement on Wednesday. A new insulin glargine product, which is approved in Europe, has won tentative approval in the United States. Sanofi SA said on Tuesday that growth in sales of its diabetes drugs would stall next year due...
Stocks rose Tuesday as investors considered earnings and an unexpected drop in orders for durable goods.
Swiss drugmaker Novartis reported better-than-expected results on Tuesday, as strong sales of new products helped offset the expiration of a key patent.
Stocks declined Monday as crude dropped below $80 a barrel and Merck & Co. narrowed its 2014 outlook.
MILAN- Italy's Monte dei Paschi di Siena is likely to try to plug a capital shortfall uncovered by Europe- wide stress tests through asset sales and possibly another cash call, but longer term a takeover could be inevitable. LONDON- Europe's banking healthcheck showed countries and lenders are implementing global capital rules at vastly different speeds, and...
Merck reported earnings that beat analysts' expectations, but global sales dropped amid patent expirations and a drop in sales of its hep C drugs.
The "Squawk on the Street" crew discusses pressures facing Merck in regards to drugs coming off patent, and the play on pharma companies.
Barbara Ryan, FTI Consulting, breaks down the numbers on Merck's quarterly results as the company appears to be reaping the rewards of R&D. Also a look ahead to Pfizer's earnings
Some of the names on the move ahead of the open.
Wall Street looked set for a lower open on Monday, as traders focused on big third-quarter earnings from Merck, T-Mobile US and Twitter.
Wall Street looked set for a lower open on Monday, ahead of big third-quarter earnings like Merck, T-Mobile US and Twitter.